These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8536375)

  • 1. Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).
    Marquart HV; Grønbaek K; Christensen BE; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Dec; 102(3):575-81. PubMed ID: 8536375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).
    Marquart HV; Svendsen A; Rasmussen JM; Nielsen CH; Junker P; Svehag SE; Leslie RG
    Clin Exp Immunol; 1995 Jul; 101(1):60-5. PubMed ID: 7621593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.
    Leslie RG
    Immunology; 1999 Jul; 97(3):371-3. PubMed ID: 10447756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
    Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
    Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
    Marquart HV; Rasmussen JM; Leslie RG
    Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.
    Tooze JA; Bevan DH
    Clin Exp Immunol; 1991 Mar; 83(3):423-9. PubMed ID: 1825940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
    Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
    Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.
    Hara T; Kojima A; Fukuda H; Masaoka T; Fukumori Y; Matsumoto M; Seya T
    Br J Haematol; 1992 Oct; 82(2):368-73. PubMed ID: 1384649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
    Leslie RG; Prodinger WM; Nielsen CH
    Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
    Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
    Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
    Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
    J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
    Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
    Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of complement receptors 1 and 2 on mouse splenic B cells using flow cytometry.
    Donius LR; Weis JH
    Methods Mol Biol; 2014; 1100():305-10. PubMed ID: 24218269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous complement activation on human B cells results in localized membrane depolarization and the clustering of complement receptor type 2 and C3 fragments.
    Løbner M; Leslie RG; Prodinger WM; Nielsen CH
    Immunology; 2009 Sep; 128(1 Suppl):e661-9. PubMed ID: 19740327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.